CL2016001082A1 - Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa - Google Patents
Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasaInfo
- Publication number
- CL2016001082A1 CL2016001082A1 CL2016001082A CL2016001082A CL2016001082A1 CL 2016001082 A1 CL2016001082 A1 CL 2016001082A1 CL 2016001082 A CL2016001082 A CL 2016001082A CL 2016001082 A CL2016001082 A CL 2016001082A CL 2016001082 A1 CL2016001082 A1 CL 2016001082A1
- Authority
- CL
- Chile
- Prior art keywords
- indolamine
- synthesis
- dioxygenase inhibitor
- dioxygenase
- inhibitor
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title abstract 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Indole Compounds (AREA)
Abstract
PROCESO PARA LA SÍNTESIS DE UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA UTIL EN EL TRATAMIENTO DEL CÁNCER E INTERMEDIARIOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901689P | 2013-11-08 | 2013-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001082A1 true CL2016001082A1 (es) | 2016-12-09 |
Family
ID=52023608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001082A CL2016001082A1 (es) | 2013-11-08 | 2016-05-05 | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US9321755B2 (es) |
| EP (2) | EP3744715A1 (es) |
| JP (4) | JP6461953B2 (es) |
| KR (2) | KR102617531B1 (es) |
| CN (2) | CN109810104B (es) |
| AR (2) | AR098343A1 (es) |
| AU (2) | AU2014346647B2 (es) |
| BR (2) | BR112016009786B1 (es) |
| CA (1) | CA2929552C (es) |
| CL (1) | CL2016001082A1 (es) |
| CR (2) | CR20190351A (es) |
| CY (1) | CY1123164T1 (es) |
| DK (1) | DK3066085T3 (es) |
| EA (2) | EA201991770A1 (es) |
| ES (1) | ES2799582T3 (es) |
| HR (1) | HRP20201089T1 (es) |
| HU (1) | HUE049337T2 (es) |
| IL (2) | IL245314B (es) |
| LT (1) | LT3066085T (es) |
| ME (1) | ME03792B (es) |
| MX (2) | MX385075B (es) |
| MY (1) | MY174254A (es) |
| PE (2) | PE20160863A1 (es) |
| PH (2) | PH12019500770B1 (es) |
| PL (1) | PL3066085T3 (es) |
| PT (1) | PT3066085T (es) |
| RS (1) | RS60598B1 (es) |
| SG (2) | SG10201803874PA (es) |
| SI (1) | SI3066085T1 (es) |
| SM (1) | SMT202000381T1 (es) |
| TW (5) | TW202440069A (es) |
| UA (1) | UA121741C2 (es) |
| WO (1) | WO2015070007A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| HRP20141094T1 (hr) | 2008-07-08 | 2015-01-16 | Incyte Corporation | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JP6461953B2 (ja) | 2013-11-08 | 2019-01-30 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | インドールアミン２，３−ジオキシゲナーゼ阻害剤の合成のためのプロセス |
| ES2856330T3 (es) * | 2014-02-04 | 2021-09-27 | Incyte Corp | Combinación de un antagonista de PD-1 y un inhibidor de IDO1 para el tratamiento del cáncer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3991749A3 (en) * | 2015-07-14 | 2022-08-24 | Kyowa Kirin Co., Ltd. | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
| WO2017079669A1 (en) | 2015-11-04 | 2017-05-11 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
| EP3389783B1 (en) * | 2015-12-15 | 2024-07-03 | Merck Sharp & Dohme LLC | Novel compounds as indoleamine 2,3-dioxygenase inhibitors |
| US9624185B1 (en) * | 2016-01-20 | 2017-04-18 | Yong Xu | Method for preparing IDO inhibitor epacadostat |
| CN105646389B (zh) * | 2016-01-28 | 2019-06-28 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 |
| CN107304191B (zh) * | 2016-04-20 | 2023-09-29 | 上海翰森生物医药科技有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 |
| WO2017181849A1 (zh) * | 2016-04-20 | 2017-10-26 | 江苏豪森药业集团有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用 |
| JP7035301B2 (ja) | 2016-08-23 | 2022-03-15 | 北京諾誠健華医薬科技有限公司 | 縮合複素環誘導体、その調製方法、及びその医学的使用 |
| EP3515914A4 (en) | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | INNOVATIVE 5- OR 8-SUBSTITUTED IMIDAZO [1,5-A] PYRIDINE AS SELECTIVE INHIBITORS OF INDOLEAMINE AND / OR TRYPTOPHANE-2,3-DIOXYGENASES |
| US11168078B2 (en) * | 2016-11-28 | 2021-11-09 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase |
| SG10201911243WA (en) | 2016-12-22 | 2020-02-27 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CN109206380A (zh) * | 2017-07-03 | 2019-01-15 | 上海时莱生物技术有限公司 | 吲哚胺2，3-双加氧酶抑制剂化合物及其制备方法和用途 |
| CN110066253B (zh) * | 2018-01-24 | 2023-06-23 | 江苏柯菲平医药股份有限公司 | 1,2,5-噁二唑类衍生物，其制备方法及其在医药中的应用 |
| CN108101899B (zh) * | 2018-02-11 | 2021-01-26 | 中国药科大学 | IDO1抑制剂Epacadostat中间体的制备方法 |
| CN109180603A (zh) * | 2018-10-10 | 2019-01-11 | 中国药科大学 | Epacadostat关键中间体的制备方法 |
| MX2022001133A (es) | 2019-08-01 | 2022-04-25 | Incyte Corp | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). |
| WO2021097317A1 (en) * | 2019-11-14 | 2021-05-20 | Nova Southeastern University | Methods and compositions for treatment of solid tumors using f16 isoindole small molecules |
| CN112341403B (zh) * | 2020-11-10 | 2022-06-28 | 南京工业大学 | 一种利用微流场反应技术制备3-氨基-4-偕胺肟基呋咱的方法 |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| BR112023017582A2 (pt) | 2021-03-05 | 2023-12-05 | Univ Basel | Composições para o tratamento de doenças ou condições associadas ao ebv |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236855A (en) | 1964-01-17 | 1966-02-22 | Merck & Co Inc | Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation |
| US3354174A (en) | 1964-02-19 | 1967-11-21 | Sterling Drug Inc | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines |
| US3553228A (en) | 1967-09-26 | 1971-01-05 | Colgate Palmolive Co | 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles |
| DE2040628A1 (de) | 1970-08-17 | 1972-02-24 | Fahlberg List Veb | Neue herbizide Mittel |
| US3948928A (en) | 1972-03-17 | 1976-04-06 | Dainippon Pharmaceutical Co., Ltd. | 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof |
| JPS5621033B2 (es) | 1973-09-05 | 1981-05-16 | ||
| FR2323683A1 (fr) | 1975-09-11 | 1977-04-08 | Philagro Sa | Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent |
| GB1501529A (en) | 1975-09-11 | 1978-02-15 | Philagro Sa | Derivatives of amidoximes |
| US4323681A (en) | 1980-09-29 | 1982-04-06 | American Home Products Corporation | 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides |
| JPS58208275A (ja) | 1982-05-20 | 1983-12-03 | Lion Corp | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 |
| DE3462259D1 (de) | 1983-07-22 | 1987-03-05 | Bayer Ag | Substituted furazans |
| US4507485A (en) | 1984-01-23 | 1985-03-26 | Bristol-Myers Company | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity |
| JPS60193968A (ja) | 1984-03-13 | 1985-10-02 | Toyo Jozo Co Ltd | シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法 |
| JPS6259283A (ja) | 1985-09-10 | 1987-03-14 | Kaken Pharmaceut Co Ltd | セフアロスポリン化合物 |
| JP2696342B2 (ja) | 1988-06-27 | 1998-01-14 | 日本曹達株式会社 | アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤 |
| ES2051986T3 (es) | 1988-07-05 | 1994-07-01 | Akzo Nv | Compuestos con actividad broncodilatadora. |
| JPH04297449A (ja) | 1991-03-27 | 1992-10-21 | Hokko Chem Ind Co Ltd | Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤 |
| JPH05186458A (ja) | 1991-04-26 | 1993-07-27 | Japan Tobacco Inc | 新規なベンゾピラン誘導体 |
| FR2677019B1 (fr) | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| JP2709677B2 (ja) | 1992-06-19 | 1998-02-04 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| FR2720396B1 (fr) | 1994-05-27 | 1996-06-28 | Adir | Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5731315A (en) | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| SK45898A3 (en) | 1995-10-17 | 1999-01-11 | Astra Pharma Prod | Pharmaceutically active quinazoline compounds |
| AU1730497A (en) | 1996-02-17 | 1997-09-02 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
| US5955495A (en) | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
| JPH11171702A (ja) | 1997-09-24 | 1999-06-29 | Takeda Chem Ind Ltd | 害虫防除方法 |
| WO1999029852A1 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
| NZ505002A (en) | 1997-12-10 | 2001-11-30 | Dainippon Ink & Chemicals | 1,2,5-oxadiazolyl, 1,2,5-thiadiazolyl or 1,2,3-thiadiazolyl oxime derivatives substituted by another heterocyclic group useful as agricultural chemicals |
| AR018424A1 (es) | 1998-06-02 | 2001-11-14 | Sumitomo Chem Takeda Agro Co | Compuesto oxadiazolina, composicion agroquimica que lo comprende y uso del mismo para la preparacion de dicha composicion |
| FR2784678B1 (fr) | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| EP1424072A1 (en) | 1999-03-03 | 2004-06-02 | Samjin Pharmaceutical Co., Ltd. | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors |
| HK1046289A1 (zh) | 1999-04-09 | 2003-01-03 | Abbott Gmbh & Co. Kg | 凝血酶抑制剂的前体药物 |
| NZ516111A (en) | 1999-05-24 | 2003-05-30 | Mitsubishi Pharma Corp | Phenoxypropylamine compounds useful to treat depression |
| JP2001158786A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 哺乳動物の外部寄生虫防除剤 |
| JP2001158785A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 農薬組成物 |
| ATE376996T1 (de) | 2000-01-13 | 2007-11-15 | Amgen Inc | Antibakterielle mittel |
| JP2001233861A (ja) | 2000-02-22 | 2001-08-28 | Ube Ind Ltd | ピラゾールオキシム化合物、その製法及び用途 |
| NZ522783A (en) | 2000-06-28 | 2004-07-30 | Smithkline Beecham P | Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| HUP0400238A2 (hu) | 2001-06-18 | 2004-07-28 | Applied Research Systems Ars Holding N.V. | Pirrolidin-oxadiazol- és tiadiazolszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények |
| AU2003218989A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia Italia S.P.A. | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| WO2003087347A1 (en) | 2002-04-12 | 2003-10-23 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| UA80131C2 (en) | 2002-05-28 | 2007-08-27 | Dimensional Pharm Inc | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7015321B2 (en) * | 2002-10-12 | 2006-03-21 | The Scripps Research Institute | Synthesis of non-symmetrical sulfamides using burgess-type reagents |
| EP1606285A4 (en) | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | NEW IDO HEMMER AND APPLICATION PROCEDURES |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| US7157476B2 (en) | 2003-08-20 | 2007-01-02 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| DK1801108T3 (da) | 2004-09-08 | 2013-02-18 | Mitsubishi Tanabe Pharma Corp | Morpholinforbindelser til behandling af inflammationer. |
| JP5065908B2 (ja) | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Ｇタンパク質結合受容体作動薬 |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
| AU2006265601A1 (en) | 2005-06-30 | 2007-01-11 | Anthrogenesis Corporation | Repair of tympanic membrane using placenta derived collagen biofabric |
| DE102005060466A1 (de) | 2005-12-17 | 2007-06-28 | Bayer Cropscience Ag | Carboxamide |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| JP4297449B2 (ja) | 2006-05-12 | 2009-07-15 | 株式会社サクラクレパス | 墨汁 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| US20080182882A1 (en) | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009128521A1 (ja) * | 2008-04-15 | 2009-10-22 | 帝人ファーマ株式会社 | システインプロテアーゼ阻害剤 |
| HRP20141094T1 (hr) | 2008-07-08 | 2015-01-16 | Incyte Corporation | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze |
| JP6461953B2 (ja) | 2013-11-08 | 2019-01-30 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | インドールアミン２，３−ジオキシゲナーゼ阻害剤の合成のためのプロセス |
-
2014
- 2014-11-07 JP JP2016528055A patent/JP6461953B2/ja not_active Expired - Fee Related
- 2014-11-07 TW TW113110214A patent/TW202440069A/zh unknown
- 2014-11-07 AR ARP140104196A patent/AR098343A1/es active IP Right Grant
- 2014-11-07 TW TW103138838A patent/TWI651311B/zh not_active IP Right Cessation
- 2014-11-07 CR CR20190351A patent/CR20190351A/es unknown
- 2014-11-07 CN CN201910026055.2A patent/CN109810104B/zh active Active
- 2014-11-07 PE PE2016000604A patent/PE20160863A1/es unknown
- 2014-11-07 EA EA201991770A patent/EA201991770A1/ru unknown
- 2014-11-07 TW TW111127236A patent/TWI859554B/zh active
- 2014-11-07 BR BR112016009786-6A patent/BR112016009786B1/pt active IP Right Grant
- 2014-11-07 BR BR122020009912-7A patent/BR122020009912B1/pt active IP Right Grant
- 2014-11-07 KR KR1020217032616A patent/KR102617531B1/ko active Active
- 2014-11-07 SG SG10201803874PA patent/SG10201803874PA/en unknown
- 2014-11-07 HR HRP20201089TT patent/HRP20201089T1/hr unknown
- 2014-11-07 TW TW109116698A patent/TWI775079B/zh active
- 2014-11-07 CN CN201480071825.0A patent/CN105899498B/zh active Active
- 2014-11-07 HU HUE14812015A patent/HUE049337T2/hu unknown
- 2014-11-07 MX MX2019008378A patent/MX385075B/es unknown
- 2014-11-07 EA EA201690959A patent/EA033667B1/ru unknown
- 2014-11-07 SG SG11201603433UA patent/SG11201603433UA/en unknown
- 2014-11-07 PH PH1/2019/500770A patent/PH12019500770B1/en unknown
- 2014-11-07 UA UAA201606159A patent/UA121741C2/uk unknown
- 2014-11-07 DK DK14812015.7T patent/DK3066085T3/da active
- 2014-11-07 EP EP20169098.9A patent/EP3744715A1/en active Pending
- 2014-11-07 MY MYPI2016000827A patent/MY174254A/en unknown
- 2014-11-07 CR CR20160252A patent/CR20160252A/es unknown
- 2014-11-07 PE PE2021001747A patent/PE20220430A1/es unknown
- 2014-11-07 KR KR1020167015077A patent/KR102370067B1/ko not_active Expired - Fee Related
- 2014-11-07 US US14/535,781 patent/US9321755B2/en active Active
- 2014-11-07 MX MX2016005954A patent/MX366874B/es active IP Right Grant
- 2014-11-07 PT PT148120157T patent/PT3066085T/pt unknown
- 2014-11-07 WO PCT/US2014/064531 patent/WO2015070007A1/en not_active Ceased
- 2014-11-07 SI SI201431604T patent/SI3066085T1/sl unknown
- 2014-11-07 PL PL14812015T patent/PL3066085T3/pl unknown
- 2014-11-07 LT LTEP14812015.7T patent/LT3066085T/lt unknown
- 2014-11-07 EP EP14812015.7A patent/EP3066085B1/en active Active
- 2014-11-07 CA CA2929552A patent/CA2929552C/en active Active
- 2014-11-07 TW TW108102217A patent/TWI696618B/zh active
- 2014-11-07 AU AU2014346647A patent/AU2014346647B2/en active Active
- 2014-11-07 RS RS20200798A patent/RS60598B1/sr unknown
- 2014-11-07 ES ES14812015T patent/ES2799582T3/es active Active
- 2014-11-07 SM SM20200381T patent/SMT202000381T1/it unknown
- 2014-11-07 ME MEP-2020-146A patent/ME03792B/me unknown
-
2016
- 2016-04-07 US US15/093,486 patent/US9873688B2/en active Active
- 2016-04-27 IL IL245314A patent/IL245314B/en active IP Right Grant
- 2016-05-02 PH PH12016500818A patent/PH12016500818B1/en unknown
- 2016-05-05 CL CL2016001082A patent/CL2016001082A1/es unknown
-
2017
- 2017-12-22 US US15/852,995 patent/US10280157B2/en active Active
-
2018
- 2018-10-02 JP JP2018187218A patent/JP6633163B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-21 AU AU2019200404A patent/AU2019200404B2/en active Active
- 2019-07-01 IL IL267773A patent/IL267773B/en active IP Right Grant
- 2019-10-07 JP JP2019184589A patent/JP6883079B2/ja not_active Expired - Fee Related
- 2019-10-07 JP JP2019184577A patent/JP6913725B2/ja active Active
-
2020
- 2020-08-05 CY CY20201100726T patent/CY1123164T1/el unknown
-
2024
- 2024-09-25 AR ARP240102568A patent/AR133922A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| MX2016010080A (es) | Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| BR112017006664A2 (pt) | terapias de combinação | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| CO2017000552A2 (es) | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 | |
| CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
| CL2017000792A1 (es) | Derivados del ácido borónico | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| AR096478A1 (es) | Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). |